Browse > Article

Bioequivalence Evaluation of Two Brands of Cefixime 100 mg Capsule (Suprax and Alpha-Cefixime) in Korean Healthy Volunteers  

Choi, Dong-Hyun (College of Medicine, Chosun University)
Burm, Jin-Pil (Chosun Nursing College)
Publication Information
Biomolecules & Therapeutics / v.15, no.3, 2007 , pp. 182-186 More about this Journal
Cefixime is an orally absorbed cephalosporin with a broad spectrum of activity against Gram-negative bacteria and is highly resistant to beta-lactamase degradation. The purpose of the present study was to evaluate the bioequivalence of two cefixime capsules, Suprax capsule (Dong-A Pharmaceutical Co., reference drug) and Alpha-Cefixime capsule (Alpha Pharmaceutical Co., test drug), according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty-four normal subjects, $23.5{\pm}3.72$ years in age and $68.3{\pm}8.89$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. There was one week washout period between the doses. After one capsule containing 100 mg of cefixime was orally administered, plasma was taken at predetermined time intervals and the concentrations of cefixime in plasma were determined using HPLC with UV detector. The pharmacokinetic parameters such as $AUC_{t}$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in $AUC_{t}$, $C_{max}$ and $T_{max}$ between two products were -3.91%, -2.23% and -3.18%, respectively, when calculated against the reference drug. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of $log0.8{\leq}{\delta}{\leq}log1.25$ (e.g., $log0.8786{\leq}{\delta}{\leq}log1.0523$ and $log0.8889{\leq}{\delta}{\leq}log1.0512$ for $AUC_{t}$ and $C_{max}$, respectively). The 90% confidence intervals using untransformed data was within ${\pm}20%$(e.g., $-10.37%{\leq}{\delta}{\leq}6.73%$ for $T_{max}$). All parameters met the criteria of KFDA for bioequivalence, indicating that Alpha-Cefixime capsule (Alpha Pharmaceutical Co.) is bioequivalent to Suprax capsule (Dong-A Pharmaceutical Co.).
bioequivalence; cefixime; suprax; cross-over study;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Asiri, Y. A., Al-Said, M. S., Al-Khamis, K. I., Niazy, E. M., El-Sayed, Y. M., Al-Rashood, K. A., Al-Yamani, M. J., Alsarra, I. A. and Al-Balla, S. A. (2005). Comparative bioavailability study of cefixime (equivalent to 100 mg/5 ml) suspension (Winex vs Suprax) in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. 43, 499-504   DOI
2 Falkowski, A. J., Look, X. M., Noguchi, H. and Silber, B. M. (1987). Determination of cefixime in biological samples by reversed phase high performance liquid chromatography. J. Chromatogr. 422, 145-152   DOI   ScienceOn
3 Faulkner, R. D., Fernandez, P., Lawrence, G., Sia, L. L, Falkowski A. J., Weiss, A. I., Yacobi, A. and Silber, B. M. (1988). Absolute bioavailability of cefixime in man. J. Clin. Pharmacol. 28, 700-706   DOI
4 Korea Food and Drug Administration. (2005). Korea guidelines for bioequivalence test 2005-31. Seoul, Korea
5 Lacy, C. F., Armstrong, L. L., Lipsy, R. J. and Lance, L. L. (1993). Drug information handbook. 13th Ed. Lexi-Comp Inc, Atlanta, pp 161-162
6 Montay, G., Masala, F., Le Roux, Y., Le Liboux, A., Uhlrich, J., Chassard, D., Thebault, J. J., Roche, G. and Frydman, A. (1991). Comparative bioavailability study of cefixime administered as tablets or aqueous solution. Drugs 42, 6-9
7 Statistical solutions Ltd. (1998). Equiv Test 1.0. Sangus, MA, USA
8 Sweetman, S. C. (2002). Martindale - The complete drug reference. 33rd Ed., Pharmaceutical Press, London, pp 166-167
9 Yom, Y. K. (2002). Bioequivalencestudy of a cefixime capsule preparation. J. Kor Soc. Hosp. Pharm. 19, 402-405
10 Mamzoridi, K., Kasteridou, N., Peonides, A. and Niopas, I. (1996). Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose. Pharmacol. Toxicol. 78, 417-420   DOI   ScienceOn